Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 82

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 82
---
MENT |

TABLE OF CONTENTS

#### EXECUTIVE COMPENSATION
(3) Consists of the applicable multiple of annual base salary and targeted annual cash bonus pursuant to the Employment Agreement (in the case of Dr. Kinney) or the Severance Plan (in the case of the other named executive officers).

(4) Consists of the in-the-money value of certain unvested nonqualified stock options as of December 31, 2024 at the closing market price per share of our ordinary shares ($13.85) on December 31, 2024, the last trading date of fiscal year 2024, which would vest in connection with the relevant termination of employment. Because no unvested stock options were in-the-money as of December 31, 2024, no value has been included here. For more information, see the footnotes to the Outstanding Equity Awards at Fiscal Year-End - Fiscal Year 2024 table above.

(5) Amounts shown are estimates of what the Company would pay in COBRA premiums for continued medical, dental and vision coverage after a qualifying termination of employment. The reported amounts (a) include only the portion of the COBRA premiums for the executive officer and his or her covered dependents that exceeds the amount the executive officer would have paid as an employee, (b) assume that the executive officer and all covered dependents do not cease to be eligible for COBRA during the relevant period, and (c) assume that the executive officer does not become eligible to receive new healthcare coverage during the relevant period.

(6) Amounts shown are estimates of what the Company would pay to provide career transition assistance to the executive officer. The reported amounts assume that the executive officer (a) commences this assistance within 60 days following the date his or her employment terminates, and (b) uses this benefit for the full 12 months it is available to the executive officer.

| Change in Control and Severance Arrangements |

| Gene G. Kinney |

Dr. Kinney, our President and Chief Executive Officer, is party to an Employment Agreement (the “Employment Agreement”), dated November 2, 2016, with Prothena Biosciences Inc ("PBI"), a wholly-owned subsidiary of the Company and Dr. Kinney’s employer (referred to in this Change in Control and Severance Arrangements section as the "Company"). The Employment Agreement was approved by our Board. The Employment Agreement provides for certain compensation to be